SCHEMBL14719639

SCHEMBL14719639

FC(F)Oc1cccc(I)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 1/20 0.46
NPSR1 Q6W5P4 3/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
MAPT P10636 2/20 0.44
RAB9A P51151 2/20 0.44
LMNA P02545 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
GAA P10253 1/20 0.42
ATM Q13315 1/20 0.42
TAS2R14 Q9NYV8 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
POLB P06746 1/20 0.40
HTT P42858 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
GRM4 Q14833 2/20 0.40
MEP1B Q16820 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29567144 1.00 DRD1 (0.46) DRD1NPSR1KMT2AMEN1MAPT
SCHEMBL255662 0.78 KMT2A (0.47) KMT2AMEN1RAB9ALMNASMN1; SMN2
SCHEMBL16294967 0.76 PPARG (0.53) DRD1NPSR1KMT2AMEN1MAPT
SCHEMBL13647240 0.74 DRD1 (0.46) DRD1NPSR1KMT2AMEN1MAPT
SCHEMBL16306421 0.74 DRD1 (0.46) DRD1NPSR1KMT2AMEN1MAPT
SCHEMBL23678581 0.74 DRD1 (0.46) DRD1NPSR1KMT2AMEN1MAPT
SCHEMBL78949 0.74 GPR3 (0.47) DAO
SCHEMBL1196373 0.74 DRD1 (0.46) DRD1NPSR1KMT2AMEN1MAPT
SCHEMBL2643752 0.74 DRD1 (0.50) DRD1NPSR1KMT2AMEN1MAPT
SCHEMBL22904 0.74 DRD1 (0.46) DRD1NPSR1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12428411-B2 Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors MERCK SHARP & DOHME LLC (US) 2025-09-30 US disclosed
US-12410159-B2 Preparation of oxindole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors MERCK SHARP & DOHME LLC (US) 2025-09-09 US disclosed
US-20250115576-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2025-04-10 US disclosed
US-12209075-B2 Pyridine-sulfonamide derivatives as sodium channel inhibitors GENENTECH, INC. (US) 2025-01-28 US disclosed
US-12186313-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-01-07 US disclosed
US-20240327391-A1 PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-10-03 US disclosed
EP-4225735-A1 PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS Merck Sharp & Dohme LLC (US) 2023-08-16 EP disclosed
CN-116457346-A Preparation of indolone derivatives as novel diacylglycerol O-acyltransferase 2 inhibitors 默沙东有限责任公司 2023-07-18 CN disclosed
CN-111655700-B Oxadiazolopyridine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors 勃林格殷格翰国际有限公司 2023-07-18 CN disclosed
EP-3746451-B1 BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2023-07-12 EP disclosed
US-20150031685-A1 SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS Dr. Reeddy's Laboratories Ltd. (IN) 2015-01-29 US disclosed
US-20150031685-A1 SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS Dr. Reeddy's Laboratories Ltd. (IN) 2015-01-29 US disclosed
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-29 US disclosed
CN-104271552-A Substituted heterocyclic acetamides as KAPPA opioid receptor (KOR) agonists REDDYS LAB LTD DR 2015-01-07 CN disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
EP-2748149-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2014-07-02 EP disclosed
WO-2013178591-A1 AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-12-05 WO disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
WO-2013027000-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 WO disclosed
US-20130052281-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327391-A1 PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS DGAT2, DGAT1, MOGAT2 DRD1 1622/4885NPSR1 3042/4885KMT2A 855/4885
US-20130052281-A1 NOVEL COMPOUNDS ABCG2, F12, UGT1A1 DRD1 705/4885NPSR1 86/4885KMT2A 3669/4885
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD DRD1 608/4885NPSR1 1960/4885KMT2A 1312/4885
US-12186313-B2 Pyridazinone compounds and their use as DAAO inhibitors PNPO, DAO, DPYD DRD1 608/4885NPSR1 1960/4885KMT2A 1312/4885
US-20150031685-A1 SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS OPRK1, OPRL1, OPRD1 DRD1 238/4885NPSR1 14/4885KMT2A 735/4885
US-12410159-B2 Preparation of oxindole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors DGAT2, DGAT1, MOGAT2 DRD1 1622/4885NPSR1 3042/4885KMT2A 855/4885
US-12428411-B2 Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors DGAT2, DGAT1, MOGAT2 DRD1 1622/4885NPSR1 3042/4885KMT2A 855/4885
US-12209075-B2 Pyridine-sulfonamide derivatives as sodium channel inhibitors SCN1B, CACNA1A, SCN1A DRD1 2028/4885NPSR1 151/4885KMT2A 1865/4885
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 DRD1 633/4885NPSR1 1330/4885KMT2A 1199/4885
US-20250115576-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF F12, REN, ZYX DRD1 1366/4885NPSR1 125/4885KMT2A 3021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.